rhIL-15联合单倍体NK细胞治疗晚期AML首次人体试验
两项1/2期试验纳入42例晚期急性髓系白血病患者,在淋巴清除化疗和单倍体NK细胞输注后给予rhIL-15(静脉或皮下)。静脉组36%患者第14天NK细胞扩增、32%达完全缓解;皮下组分别为27%和40%。皮下给药出现细胞因子释放综合征(56%)而静脉给药未出现。
要点
- rhIL-15联合单倍体NK细胞可使部分晚期AML患者达完全缓解。
- 静脉与皮下rhIL-15的NK细胞扩增率分别为36%和27%,缓解率分别为32%和40%。
- 皮下rhIL-15出现细胞因子释放综合征(56%),对激素和托珠单抗有反应。
核心结论
- rhIL-15诱导的体内NK细胞扩增和缓解率优于既往IL-2试验,但皮下给药出现细胞因子释放综合征。
研究设计与样本
- 两项1/2期试验:42例患者接受淋巴清除化疗和单倍体NK细胞后给予rhIL-15;1期试验(NCT01385423)26例静脉给药,2期试验(NCT02395822)16例皮下给药。
主要发现
- 1期试验中26例患者36%第14天有显著NK细胞扩增,32%达完全缓解。
- 2期试验中16例患者27%第14天有NK细胞扩增,40%达缓解。
- 皮下rhIL-15组56%出现细胞因子释放综合征,其中9例中5例合并神经毒性,对激素和托珠单抗有反应。
- 皮下给药较静脉给药清除更慢、IL-6水平更高。
关键数值与推荐
- 1期试验rhIL-15剂量递增0.3-1.0 μg/kg,连续12天给药。
- 2期试验皮下rhIL-15剂量2.0 μg/kg,每日一次共10次。
临床怎么用
- 基于药代动力学和药效学的给药方案可能保留IL-15的治疗获益并减少细胞因子释放综合征。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In vivo expansion of haploidentical natural killer (NK) cell infusions with interleukin-2 (IL-2) can induce remission of refractory acute myeloid leukemia, but efficacy may be hampered by concurrent stimulation of host regulatory T cells. To overcome this limitation, we substituted the NK homeostatic factor IL-15 in 2 phase 1/2 trials. Forty-two patients received either intravenous (IV) (NCT01385423) or subcutaneous (SC) (NCT02395822) recombinant human IL-15 (rhIL-15) after lymphodepleting chemotherapy and haploidentical NK cells. Escalating doses of rhIL-15 (0.3-1.0 μg/kg) were given on 12 consecutive days in a phase 1 trial. Of 26 patients, 36% had robust in vivo NK-cell expansion at day 14, and 32% achieved complete remission. Hypothesizing that SC dosing of rhIL-15 would be safer and better tolerated, 16 patients received 10 once per day doses of SC rhIL-15 at 2.0 μg/kg on a phase 2 trial. NK-cell expansion at day 14 was seen in 27% of the patients, and 40% achieved remission. rhIL-15 induced better rates of in vivo NK-cell expansion and remission compared with previous trials with IL-2, but it was associated with previously unreported cytokine release syndrome (CRS) after SC but not IV dosing. CRS was observed in 56% of patients given SC rhIL-15 (with concurrent neurologic toxicity in 5 of 9 patients) and was responsive to steroids and tocilizumab. SC administration was associated with slower pharmacokinetic clearance and higher levels of IL-6 than IV dosing. These novel trials testing the use of IL-15 to potentiate cell therapy suggest that dosing schedules based on pharmacokinetics and pharmacodynamics will preserve the therapeutic benefits of IL-15 and minimize CRS. These trials were registered at www.clinicaltrials.gov as #NCT01385423 and #NCT02395822.
引用
- Cooley S, He F, Bachanova V, et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 2019. PMID: 31266741. doi:10.1182/bloodadvances.2018028332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。